PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$58.00

24 Sep
2021

-0.930

OPEN

$58.82

-1.58%

HIGH

$59.00

108,792

LOW

$57.88

TARGET
$54.49 -6.1% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 29.6 42.0 xxx
DPS (cps) xxx 15.0 19.0 xxx
EPS Growth xxx 33.4% 41.8% xxx
DPS Growth xxx 25.0% 26.7% xxx
PE Ratio xxx N/A 138.1 xxx
Dividend Yield xxx N/A 0.3% xxx
Div Pay Ratio(%) xxx 50.6% 45.2% xxx

Dividend yield today if purchased 3 years ago: 1.22%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.26

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - 8c (100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx29.6
DPS All xxxxxxxxxxxxxxx15.0
Sales/Revenue xxxxxxxxxxxxxxx67.9 M
Book Value Per Share xxxxxxxxxxxxxxx78.4
Net Operating Cash Flow xxxxxxxxxxxxxxx39.0 M
Net Profit Margin xxxxxxxxxxxxxxx45.45 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx27.89 %
Return on Equity xxxxxxxxxxxxxxx43.49 %
Return on Total Capital xxxxxxxxxxxxxxx57.75 %
Capex xxxxxxxxxxxxxxx7.7 M
Capex % of Sales xxxxxxxxxxxxxxx11.33 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx25.3 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

19/08/2021

5

Reduce

$54.49

-6.05%

The FY21 results for Pro Medicus were lower than Morgans and consensus expectations though strong earnings (EBITDA) margins were a standout. A 735 basis points (bps) improvement exceeded the assumed 335bps uplift.

The broker lifts its price target to $54.49 from $49.69 and retains its Reduce rating and advocates holders with outsized positions trim into price strength. While FY21 margins continued to expand, they are expected to be less pronounced in FY22 as in-person trade shows and conference costs recommence.

The analyst highlights the signing of research collaboration agreements with NYU Langone Health and Mayo Clinic. In addition, the February FDA approval for the company’s Breast Density AI Algorithm is considered positive.

FORECAST
Morgans forecasts a full year FY22 dividend of 19.00 cents and EPS of 42.00 cents.
Morgans forecasts a full year FY23 dividend of 22.00 cents and EPS of 49.00 cents.

PME STOCK CHART